Clinical Trials Logo

Hepatic Insufficiency clinical trials

View clinical trials related to Hepatic Insufficiency.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06390410 Not yet recruiting - Clinical trials for Hepatic Insufficiency

A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function

Start date: July 10, 2024
Phase: Phase 1
Study type: Interventional

Evaluate simufilam levels in the blood of hepatically impaired individuals compared to Healthy individuals of similar demographics

NCT ID: NCT06387160 Not yet recruiting - Clinical trials for Acute-On-Chronic Liver Failure

To Determine the Predictors of Reversibility for Acute-on-Chronic Liver Failure at 6-months.

Start date: April 20, 2024
Phase:
Study type: Observational

ACLF is defined differently in APASL,EASL and AASLD.APASL talks of reversibility in ACLF as per its definition and constitution of Homogenous population with ACLF.The definition of ACLF as per APASL is an acute hepatic insult manifesting as jaundice (serum bilirubin ≥ 5 mg/dL (85 micromol/L) and coagulopathy (INR ≥ 1.5 or prothrombin activity <40%) complicated within 4 weeks by clinical ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease/cirrhosis, and is associated with a high 28-day mortality .From the point of view of intensivists, events in form of organ dysfunction , failure or mortality would cumulatively effect the outcome.Reversibility of ACLF syndrome is a feature of the ACLF defined by the AARC criteria, as nearly all the patients included are after the index presentation.With mitigation of the acute insult and over time, the hepatic reserve improves ,fibrosis regresses and the portal pressure decreases. Further, unlike patients with decompensated cirrhosis and similar to patients with ALF, the reversal of coagulopathy preceded the reversal of jaundice,that is ,median time to reversal of syndrome, i.e jaundice and coagulopathy was 7 (4-30)days versus 19 (7-60)days for jaundice, respectively. The median time for reversal of syndrome, i.e, jaundice and coagulopathy ,was 30 days. Baseline albumin, AARC score and Transient elastography predicted long term reversibility .The disease severity assessment is needed for prognostication and to guide the therapy. Furthermore,the available prediction scores have been validated at baseline,but none has been evaluated in a dynamic manner for prognostication in ACLF patients.A DYNAMIC Model that could predict the reversibility in ACLF is urgently required.

NCT ID: NCT06377774 Not yet recruiting - Clinical trials for Acute-On-Chronic Liver Failure

To Optimize Therapeutic Procedures of DPMAS in ACLF Patients: a Prospective, Sigle Arm and Multicenter Study

Start date: May 1, 2024
Phase:
Study type: Observational [Patient Registry]

Acute-on-chronic liver failure (ACLF) is a life-threaten syndrome carrying high-short-term mortality raging 40% to 60% within 90 days in patients with chronic liver disease. Double plasma molecular adsorption system (DPMAS) is one of the available artificial liver support systems, which combines plasma filtration and two specific adsorption membranes dedicating to remove bilirubin and the middle molecular toxins respectively. The efficiency of DMPAS treatment in liver failure patients remains controversial. Previous study indicate that liver failure patients with DPMAS therapy improve the short-term mortality and prevent the diseases progression within 28 days (PADSTONE Study). Thus, this single-arm, multicenter and prospective study is to further validate and optimize the therapeutic procedures of DPMAS therapy in ACLF patients.

NCT ID: NCT06340269 Not yet recruiting - Clinical trials for Multiple Organ Failure

Feasibility Pilot Study to Evaluate the Safety and Performance of the MEX-CD1 Medical Device in ACLF

MexACLF
Start date: May 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test the MEX-CD1 hemodialysis medical device in patients suffering from ACLF. The main questions it aims to answer are: - Is the device safe when used according to the instructions for use? - Does the device work as expected by removing the excess of free copper from the blood? Patients will receive 3 MEX-CD1 Slow Low volume CVVHD within 1 week.

NCT ID: NCT06285253 Not yet recruiting - Acute Liver Failure Clinical Trials

miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial

Start date: May 1, 2024
Phase: Phase 1
Study type: Interventional

The clinical trail will assess the safety of miroliverELAP for the treatment of acute liver failure without underlying chronic liver disease. miroliverELAP is an external liver assist combination product consisting of a single-use MIRO-001 bioengineered liver graft and an extracorporeal blood circuit. miroliverELAP Is intended to support the native (failed) liver for up to 48-hours of continuous treatment to allow time for liver recovery or to identify a transplantable liver.

NCT ID: NCT06272071 Not yet recruiting - Liver Failure Clinical Trials

A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of Severe Hepatitis (Liver Failure) Complicated With Infection

Start date: March 2024
Phase:
Study type: Observational

The goal of this observational study is to expound the population and characteristics of pathogenic microorganisms with co-infection, draw the pedigree of pathogenic microorganisms, and evaluate its influence on disease outcome in patients with severe hepatitis (liver failure). The main questions it aims to answer are: - Mapping of infectious agents in patients with severe hepatitis (liver failure) - Constructing early warning predictive models to explore how to give an individualized regimen of integrated immune function.

NCT ID: NCT06190002 Not yet recruiting - Clinical trials for Acute-on-chronic Hepatitis B Liver Failure

Characteristics and Risk Factors for Invasive Fungal Infection With Acute-on-chronic Hepatitis B Liver Failure

Start date: January 20, 2024
Phase:
Study type: Observational

This is a single-center retrospective study. The clinical data of patients with Acute-on-chronic Hepatitis B liver failure who were hospitalized in the Department of Hepatology, Qilu Hospital of Shandong University from January 2010 to July 2023 were collected.

NCT ID: NCT06187220 Not yet recruiting - Acute Liver Failure Clinical Trials

Plasma Exchange for Amanita Toxin-induced Acute Liver Failure

Amanita-Pex
Start date: January 2024
Phase:
Study type: Observational

Retrospective evaluation of the value of additive therapeutic plasma exchange (PEX) compared to standard medical therapy (SMT) in Amanita toxin-associated acute liver failure in children and adolescents within the last 10 years at a international group of liver transplant centers.

NCT ID: NCT06181318 Not yet recruiting - Liver Cancer Clinical Trials

Quantitative MRI and Outcomes of Liver Resection

Start date: February 1, 2024
Phase:
Study type: Observational

The present observational study aims to assess the benefit of this quantitative multiparametric magnetic resonance imaging (MRI) in clinical practice, to quantify future liver remnant performance, and to accurately predict the risk of liver failure after major hepatectomy, among patients undergoing major liver resection. The main questions to be answered are: - Can multiparametric MRI predict the postoperative liver function? - Can multiparametric MRI predict the postoperative liver-specific complications as well as mortality? With ethical approval and fully informed consent, patients being considered for major liver resection will undergo clinical assessment, blood sampling, and multiparametric MRI before surgery. For the primary outcome, 33 participants will be needed to detect a minimum correlation coefficient of 0.2 with 5% significance and 80% power.

NCT ID: NCT06142968 Not yet recruiting - Clinical trials for Acute-On-Chronic Liver Failure

Acute on Chronic Liver Failure in Cirrhotic Patients at Assiut University Hospitals

Start date: December 2023
Phase:
Study type: Observational

ACLF is a distinct syndrome that is different from chronic progressive hepatic decompensation. In most cases of ACLF, patients present initially with clinical manifestations of a decompensating event, usually renal impairment, worsening of abdominal ascites, jaundice or Hepatic encephalopathy (HE) and often precipitated by bacterial infection.